Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo ...

Winter break for me and other international students is a waiting period for the next semester,” said June Han, a second-year Calvin University student from the Dominican Republic. For those few weeks ...

Administrators said the updates will expand access to high-demand classes and make summer enrollment more affordable.

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

The US government whipped up claims of “agroterrorism” over the use of harmless, common lab research materials.

Neither is “How’s That?!” It’s a fictitious show within a show, in the third season of “The Comeback,” the HBO series ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...

Cibus, Inc. (Nasdaq: CBUS) (the 'Company'), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ...

This doesn’t reside with Pixar's best work but it sits comfortably in that next, altogether respectable tier.

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) ...